meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
ipilimumab plus gp100
ipilimumab plus SoC
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (2mg/kg)
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Immunostimulant
vs vaccine
vs gp100
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (brain) NO
metastasis (brain) YES
PD-L1 < 1%
PD-L1 < 5%
PD-L1 > 1%
PD-L1 > 5%
previous systemic treatment (%)
previous systemic treatment NO (%)
stage M0
stage M0/M1A/M1B
stage M1A
stage M1B
stage M1C
stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
deaths (OS) (extension)
DOR
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Abdominal pain TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Chills TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Eye disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Guillain-Barré syndrome TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Nervous system disorders TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pancytopenia TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Pericarditis TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Polymyalgia Rheumatica TRAE (grade 3-4)
Pruritic rash TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Chills AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Nausea AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
DCR
mML - L2 - all population
metastatic/adv melanoma (mML)
mML - 2nd line (L2)
mML - L2 - all population
versus gp100
ipilimumab alone vs. gp100
1
-
ipilimumab plus gp100 vs. gp100
1
-
versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone
1
361 [-303; 1024]
/10000
115/365 vs. 101/362
ipilimumab plus gp100 vs. ipilimumab alone
1
-
pembrolizumab (10mg/kg) vs. ipilimumab alone
1
-
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone
1
-
versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC
1
304 [-509; 1118]
/10000
83/250 vs. 76/252
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC)
1
-
pembrolizumab (10mg/kg) vs. Standard of Care (SoC)
1
-
pembrolizumab (2mg/kg) vs. Standard of Care (SoC)
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open